Chemotherapy Plus Endocrine Therapy Increases Cognitive Impairment in Breast Cancer
Patients with breast cancer may be at risk for more intense cognitive impairment following treatment with chemotherapy plus endocrine therapy.
Switch Maintenance Regimens Demonstrate Similar Efficacy for Patients with RAS Wild-Type mCRC
ASH Data Offer Treatment Direction for Oncology Nursing Professionals
HRQOL Analysis Favors Tislelizumab Over Sorafenib in Hepatocellular Carcinoma
Encorafenib Triplet Elicits Antitumor Activity in BRAF V600E+ mCRC
2 Clarke Drive Cranbury, NJ 08512